ProLynx Issues U.S. Patent Covering Beta-Eliminative Linkers
3/26/2014 9:46:00 AM
SAN FRANCISCO, March 25, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs – peptides, proteins and small molecules - today announced that the United States Patent and Trademark Office has issued US Patent 8,680,315 covering beta-eliminative linkers that release active drug from conjugates over prolonged periods.
Help employers find you! Check out all the jobs and post your resume.
comments powered by